SK18122002A3 - Protilátky proti ľudskému MCP-1 - Google Patents

Protilátky proti ľudskému MCP-1 Download PDF

Info

Publication number
SK18122002A3
SK18122002A3 SK1812-2002A SK18122002A SK18122002A3 SK 18122002 A3 SK18122002 A3 SK 18122002A3 SK 18122002 A SK18122002 A SK 18122002A SK 18122002 A3 SK18122002 A3 SK 18122002A3
Authority
SK
Slovakia
Prior art keywords
mcp
amino acid
ser
gly
antibody
Prior art date
Application number
SK1812-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Peter Hiestand
Hans Hofstetter
Trevor Glyn Payne
Roman Urfer
Padova Franco E. Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK18122002A3 publication Critical patent/SK18122002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK1812-2002A 2000-06-30 2001-06-29 Protilátky proti ľudskému MCP-1 SK18122002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds
PCT/EP2001/007468 WO2002002640A2 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1

Publications (1)

Publication Number Publication Date
SK18122002A3 true SK18122002A3 (sk) 2003-06-03

Family

ID=9894801

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1812-2002A SK18122002A3 (sk) 2000-06-30 2001-06-29 Protilátky proti ľudskému MCP-1

Country Status (27)

Country Link
US (1) US20040047860A1 (cg-RX-API-DMAC10.html)
EP (1) EP1299421B1 (cg-RX-API-DMAC10.html)
JP (2) JP3920215B2 (cg-RX-API-DMAC10.html)
KR (1) KR100603899B1 (cg-RX-API-DMAC10.html)
CN (1) CN100486996C (cg-RX-API-DMAC10.html)
AR (1) AR046379A1 (cg-RX-API-DMAC10.html)
AT (1) ATE426616T1 (cg-RX-API-DMAC10.html)
AU (2) AU8390301A (cg-RX-API-DMAC10.html)
BR (1) BR0112086A (cg-RX-API-DMAC10.html)
CA (1) CA2412775A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20024256A3 (cg-RX-API-DMAC10.html)
DE (1) DE60138102D1 (cg-RX-API-DMAC10.html)
EC (1) ECSP024402A (cg-RX-API-DMAC10.html)
ES (1) ES2322643T3 (cg-RX-API-DMAC10.html)
GB (1) GB0016138D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0301477A3 (cg-RX-API-DMAC10.html)
IL (1) IL153721A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA03000201A (cg-RX-API-DMAC10.html)
NO (1) NO20026063L (cg-RX-API-DMAC10.html)
NZ (1) NZ523195A (cg-RX-API-DMAC10.html)
PE (1) PE20020125A1 (cg-RX-API-DMAC10.html)
PL (1) PL207133B1 (cg-RX-API-DMAC10.html)
PT (1) PT1299421E (cg-RX-API-DMAC10.html)
RU (1) RU2314316C2 (cg-RX-API-DMAC10.html)
SK (1) SK18122002A3 (cg-RX-API-DMAC10.html)
WO (1) WO2002002640A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200300199B (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
EP2990394A1 (en) 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
CA2497804A1 (en) * 2002-09-12 2004-03-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-human mcp-1 antibody and fragment of said antibody
US20050232923A1 (en) * 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
TW200716174A (en) * 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
EP2041568A4 (en) * 2006-06-15 2009-08-12 CCR2 ANTAGONISTS FOR CHRONIC BREATHING REACTIONS IN ORGAN TRANSPLANTATIONS
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
BRPI0718225A2 (pt) * 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
AU2007337983A1 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
US20100254992A1 (en) * 2007-06-29 2010-10-07 Anuk Das Anti-mcp-1 antibodies, compositions, methods and uses
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
CN102239180B (zh) 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
ES2533493T3 (es) 2008-08-20 2015-04-10 Probiodrug Ag Anticuerpos dirigidos contra la proteína 1 quimioatrayente de monocitos (MCP-1 N1pE) de piroglutamato
CA2765949C (en) * 2009-06-25 2016-03-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
CN105051065A (zh) 2012-06-22 2015-11-11 索伦托治疗有限公司 与ccr2结合的抗原结合蛋白
EP3180026A4 (en) * 2014-08-15 2018-04-11 Pixarbio Corporation Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
CN105695495B (zh) * 2015-12-07 2020-02-18 中国石油大学(华东) 一种高活性人趋化因子的制备方法及用途
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
BR112022012010A2 (pt) * 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN119684454B (zh) * 2024-12-25 2025-09-12 武汉爱博泰克生物科技有限公司 针对人mcp-1蛋白的抗体、抗体对和试剂盒及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019552D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US7371825B2 (en) * 2004-06-30 2008-05-13 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
DE60138102D1 (de) 2009-05-07
AR046379A1 (es) 2005-12-07
PT1299421E (pt) 2009-06-26
RU2314316C2 (ru) 2008-01-10
CN1443199A (zh) 2003-09-17
MXPA03000201A (es) 2003-05-27
KR100603899B1 (ko) 2006-07-25
CA2412775A1 (en) 2002-01-10
KR20030014272A (ko) 2003-02-15
NZ523195A (en) 2005-09-30
NO20026063D0 (no) 2002-12-17
JP2007054079A (ja) 2007-03-08
AU8390301A (en) 2002-01-14
BR0112086A (pt) 2003-05-06
PE20020125A1 (es) 2002-03-12
WO2002002640A2 (en) 2002-01-10
US20040047860A1 (en) 2004-03-11
ZA200300199B (en) 2003-11-13
PL207133B1 (pl) 2010-11-30
EP1299421A2 (en) 2003-04-09
GB0016138D0 (en) 2000-08-23
WO2002002640A3 (en) 2002-05-16
CZ20024256A3 (cs) 2003-04-16
AU2001283903B2 (en) 2005-06-02
NO20026063L (no) 2003-02-27
ECSP024402A (es) 2003-02-06
IL153721A0 (en) 2003-07-06
HUP0301477A3 (en) 2005-11-28
PL359854A1 (en) 2004-09-06
ATE426616T1 (de) 2009-04-15
HUP0301477A2 (hu) 2003-08-28
JP2004502421A (ja) 2004-01-29
ES2322643T3 (es) 2009-06-24
CN100486996C (zh) 2009-05-13
JP3920215B2 (ja) 2007-05-30
EP1299421B1 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
EP1299421B1 (en) Antibodies to human mcp-1
KR102256152B1 (ko) Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도
EP2242771B1 (en) Binding molecules to the human ox40 receptor
EP1871807B1 (en) Antibodies against cxcr4 and methods of use thereof
AU2001283903A1 (en) Antibodies to human MCP-1
US12098195B2 (en) Anti-IL-23p19 antibody and use thereof in treating diseases
MXPA02007091A (es) Anticuerpos para il-1b humana.
US20210009706A1 (en) Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof
AU2020322588A1 (en) Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
AU2017313632B2 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
WO2005060457A2 (en) Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
AU2018202095B2 (en) Binding Molecules to the Human OX40 Receptor
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体
EA052903B1 (ru) Антитело к cd40, биспецифическое антитело к pd-l1×cd40 и их применение
AU2014202213A1 (en) Binding Molecules to the Human OX40 Receptor

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure